Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Nuvectis Pharma, Inc. (NVCT) had Normalized Pre-Tax Income of $-26.44M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-28.87M |
|
-- |
|
-- |
|
$27.57M |
|
$-27.57M |
|
$1.13M |
|
$-26.44M |
|
|
Normalized Pre-Tax Income |
$-26.44M |
$-26.44M |
|
$-26.44M |
|
$-26.44M |
|
$-26.44M |
|
$-27.57M |
|
$-27.57M |
|
21.81M |
|
21.81M |
|
$-1.32 |
|
$-1.32 |
|
| Balance Sheet Financials | |
$31.71M |
|
-- |
|
-- |
|
$31.71M |
|
$13.30M |
|
-- |
|
-- |
|
$13.30M |
|
$18.41M |
|
$18.41M |
|
$18.41M |
|
25.68M |
|
| Cash Flow Statement Financials | |
$-16.01M |
|
-- |
|
$29.11M |
|
$18.53M |
|
$31.63M |
|
$13.10M |
|
$6.03M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.38 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-16.01M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-143.60% |
|
-143.61% |
|
-83.39% |
|
-143.61% |
|
$0.72 |
|
$-0.73 |
|
$-0.73 |
|